Although levodopa is still recognized as the most effective medication for PD, long-term treatment is often associated with motor complications [17], which impair daily living and have a negative impact on a patient’s QoL. Since WO is generally the first motor complication to develop, its early identification is of great importance for the timely optimization of therapy [8].
The overall prevalence rate of WO in this study was 35.3% (Table 2), which was nearly identical to that reported in another Japanese survey in 407 patients from the Japan Parkinson Disease Association, where 36% of patients, with a mean age of 69 years and disease duration ranging from 3–9 years, reported WO [18]. Results from this study highlighted the low awareness of WO among patients compared with both the physician assessment and the WOQ-9, which suggests that patients do not easily recognize the early signs of WO. In line with previous reports [10, 11], our study confirmed that differences in the perception of WO exist between patients and their physicians, as evidenced by the fact that WO was observed in 46.0% of patients by physician assessment and in 35.3% of patients by patient self-awareness. On the other hand, WOQ-9 could detect WO with high sensitivity. The WOQ-9 identified WO in 67.2% of patients compared with the physician assessment that identified WO in only 46.0% of patients (Table 2). We considered that patients with WOQ-9 scores ≥ 2 were having WO according to our previous study [15], which showed that sensitivity and specificity for WOQ-9 scores ≥ 2 were 87.1% and 72.2%, respectively, while those for WOQ-9 scores ≥ 1 were 94.1% and 39.2%, respectively. Therefore, WOQ-9 scores ≥ 2 might help the avoiding false positive and maintain high sensitivity. These findings may be attributable to the clear and concise nature of the WOQ-9, which makes it quick and simple to use. In contrast, busy physicians may not always have sufficient time to adequately ask their patients about potential symptoms of WO [10]. Therefore, the WOQ-9 can be an effective screening tool that aids in the diagnosis of WO in patients with PD.
Morning akinesia, which is common in patients with PD, not only causes significant disability but also has a negative impact on a patient’s QoL [19, 20]. Indeed, results from a European, multicenter, observational study reported that up to 60% of patients experience morning akinesia, which prevents them from performing morning routines [20]. In our study, patients recognized morning akinesia to a greater extent than physicians, with 58.7% of patients reporting morning akinesia compared with 48.9% of physicians (Table 2). This finding is in line with the results of an Italian survey in 151 consecutive patients, which reported that 64.2% of patients were able to recognize morning akinesia [21]. Taken together, these findings suggest that patients easily recognize the presence of morning akinesia and are therefore more likely to discuss any concerns with their physicians [19]. Moreover, results from our study showed that patients were far more likely to recognize morning akinesia than WO. In contrast, physicians reported similar rates of akinesia and WO (48.9% and 46.0%, respectively). Consequently, there may be a perception among some physicians that patients are able to identify the early symptoms of WO as easily as those of morning akinesia; however, due to the heterogeneity of the signs and symptoms of WO, patients frequently underrecognize WO, a finding that was observed in our study [10].
Episodes of dyskinesia are a major challenge in the long-term management of patients with PD [22]. It is therefore unsurprising that troublesome dyskinesia was reported by 34.0% of patients, an observation that corroborates findings from previous studies where treatment-induced dyskinesia occurred in 28.0–40.0% of patients [6, 22]. Dyskinesia, as well as morning akinesia, were underreported by a greater number of physicians compared with patients, highlighting the need for careful and accurate sharing of information between patients and their physicians.
Since PD significantly impacts health-related QoL, this study used the PDQ-8 to assess health-related QoL. As expected, PD had a negative impact on patient QoL, which was, in general, consistently reported by both patients and physicians. Interestingly, bodily discomfort was poorly recognized by physicians, a finding that may be attributable to a number of reasons, including the patient's disease profile, pain threshold, the part of the body examined, and the timing of assessment in relation to drug administration [23, 24].
The results from this study showed worsened QoL among patients for which both physician and WOQ-9 assessments were positive but patient self-assessments were negative compared with patients for which physician and WOQ-9 assessments and patient self-assessments all were negative (Supplemental Table 5). These data support the hypothesis that patients often underestimate their WO, and therefore, which worsened QoL without awareness. Regarding morning akinesia, worsened QoL was observed among patients for which patient self-awareness was positive but physician assessment was negative compared with those for which both patient self-awareness and physician assessment were negative (Supplemental Table 6). Interestingly, PDQ-8 SI assessed by patients and physicians showed similar scores, which suggests that physicians realized the deteriorated QoL of patients, but did not consider their morning akinesia as the reason of it.
There are some limitations to our study. First, there are limitations inherent to these types of surveys, and some patients may have been unable to complete the questionnaires because of their physical restrictions. In addition, this survey may have been susceptible to biases such as responder bias, recall bias, and interviewer bias. Along with the well-known limitations of noninterventional and cross-sectional studies, the sample size was also relatively small. Finally, as the focus of the study was on Japan, the generalizability of the results is unclear. However, despite these limitations, results from this study emphasize the importance of using effective screening tools, such as the WOQ-9, to aid physicians in the diagnosis of WO. Moreover, these findings highlight the need for an open dialogue and effective communication and collaboration between patients and physicians. In addition, recent advances in digital technology and biotechnology have led to the development of many types of wearable sensor systems, enabling the continuous long-term monitoring of motor complications [25, 26]. These sensors, which are unobtrusive and accurate, should further assist physicians in diagnosing and managing the symptoms of WO.